LDV Capital's Annual General Meeting 2025: The Visual Tech & AI Experts Building The Future

LDV Capital's Annual General Meeting 2025: The Visual Tech & AI Experts Building The Future

We are thrilled to share a few photographs and stories from this year’s invite-only Annual General Meeting – a special event where our LPs connect in person with our team, portfolio companies and experts.

It was a pleasure to host entrepreneurs, investors, researchers and special guests such as Maria Gotsch, Andy Parsons, Brian Cohen, Mark Kalow, Fernando De La Torre, Kristin Dana, Carlos Bhola, Thomas Knox, Matthew Zeiler, Rebekah Griesenauer, Hani Eskandari, Omar Issa, Rebecca Paoletti, Robert Levitan, Andres Glusman, Seth Haberman, Kelly Hoey, Medha Vedaprakash, Emi Gal, Adam Maher, Summer Bedard, Dave Zohrob, Dawn Barber, Jeremiah Robison and many more!

Our Annual General Meeting was a true highlight – full of thoughtful conversations, valuable insights and genuine connection. We’re grateful to everyone who joined us and contributed to making it a success!

Read More

Thank you for Making our 11th Annual LDV Vision Summit a Great Success! Check out highlights, videos, insights

Thank you for Making our 11th Annual LDV Vision Summit a Great Success! Check out highlights, videos, insights

Our 11th Annual LDV Vision Summit was our most attended event to date, bringing together deep tech entrepreneurs, technologists, academics, researchers and investors for engaging discussions on cutting-edge visual tech and AI innovations. We were thrilled to welcome speakers from Sequoia Capital, NVIDIA, IBM, Kleiner Perkins, Phare Bio, IVP, Mitra Chem, BAM Corner Point, Duke University, Fortune, Argonne National Laboratory, Princeton University, The Pioneer Centre for Artificial Intelligence and Fieldstone Bio. Three of our LDV Capital portfolio companies also presented: Synthesia, DANNCE AI and ResiQuant.

Read More

AI in Neuroscience: Partnering with DANNCE.AI to Increase Drug Efficacy & Improve the Lives of People with Movement Disorders

AI in Neuroscience: Partnering with DANNCE.AI to Increase Drug Efficacy & Improve the Lives of People with Movement Disorders

DANNCE.AI is bringing to market a novel phenotyping platform to digitize the clinical assessments used by clinicians and drug developers to quantify movement. We led their $2.6M pre-seed round along with co-investors Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio.

Read More